Optimizing Adjuvant Breast Cancer Chemotherapy: Rationale for the MA.21 Study
May 1st 2001Recently initiated is a phase III randomized trial (MA.21 trial) of adjuvant chemotherapy for node-positive and high-risk node-negative, premenopausal and postmenopausal (£ 60 years) women with breast cancer who have